Equities

Guerbet SA

Guerbet SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)26.00
  • Today's Change-0.300 / -1.14%
  • Shares traded12.55k
  • 1 Year change+44.44%
  • Beta0.7504
Data delayed at least 15 minutes, as of Nov 22 2024 15:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments10293165
Total Receivables, Net150121119
Total Inventory305272202
Prepaid expenses151210
Other current assets, total9.94100.00
Total current assets582510495
Property, plant & equipment, net294286274
Goodwill, net292740
Intangibles, net6870149
Long term investments252923
Note receivable - long term------
Other long term assets----0.00
Total assets1,0259401,001
LIABILITIES
Accounts payable10511695
Accrued expenses654957
Notes payable/short-term debt0.250.250.17
Current portion long-term debt/capital leases9.293333
Other current liabilities, total504151
Total current liabilities229240237
Total long term debt374278299
Total debt384311333
Deferred income tax9.459.8715
Minority interest(0.06)----
Other liabilities, total343244
Total liabilities647560596
SHAREHOLDERS EQUITY
Common stock131313
Additional paid-in capital------
Retained earnings (accumulated deficit)414404441
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(49)(37)(48)
Total equity378380405
Total liabilities & shareholders' equity1,0259401,001
Total common shares outstanding131313
Treasury shares - common primary issue0.020.020.01
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.